Can I Take Quercetin with Dayvigo (Lemborexant)?

How Dayvigo Works and Why Metabolism Matters

Dayvigo (lemborexant) blocks orexin-1 and orexin-2 receptors in the brain, reducing wakefulness signals so sleep can begin. The FDA approved it in December 2019 at 5 mg and 10 mg doses for adults with insomnia characterized by difficulty falling or staying asleep. Its efficacy was established in two phase 3 trials, SUNRISE-1 and SUNRISE-2, enrolling more than 1,900 patients combined [1][2].

CYP3A4: The Rate-Limiting Enzyme

Lemborexant is metabolized almost entirely by cytochrome P450 3A4 (CYP3A4). According to the FDA-approved prescribing information, co-administration with the strong CYP3A4 inhibitor itraconazole increased lemborexant area under the curve (AUC) by approximately 4-fold [3]. That finding drove a black-box-level contraindication: Dayvigo must not be taken with strong CYP3A4 inhibitors. For moderate CYP3A4 inhibitors, the label recommends a maximum dose of 5 mg [3].

Why This Matters for Supplements

Any compound that slows CYP3A4 activity can, in theory, raise lemborexant plasma concentrations. The clinical question is whether quercetin inhibits CYP3A4 enough to cross the threshold from theoretical concern to practical risk.

Quercetin's Effect on CYP3A4

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is one of the most abundant dietary flavonoids. Supplement doses typically range from 500 mg to 1,000 mg per day, far exceeding the estimated 10 to 100 mg obtained from food alone [4].

In Vitro Evidence

Multiple in vitro studies demonstrate that quercetin inhibits CYP3A4 with IC50 values in the low micromolar range (1 to 10 μM), depending on the substrate and assay system. A 2009 study in Drug Metabolism and Disposition measured quercetin's inhibitory constant (Ki) against CYP3A4-mediated midazolam hydroxylation at approximately 1.1 μM [5]. That potency places quercetin in the moderate-to-strong inhibitor range when concentrations are high enough at the enzyme site.

In Vivo Translation

The gap between test-tube potency and whole-body relevance is significant. Oral bioavailability of quercetin is low, typically between 2% and 17% depending on the formulation [4]. A pharmacokinetic study published in the European Journal of Clinical Pharmacology found that 500 mg quercetin increased the AUC of the CYP3A4 substrate cyclosporine by roughly 36% in healthy volunteers, consistent with weak-to-moderate CYP3A4 inhibition in vivo [6]. Another study using midazolam as a probe substrate found a more modest 15% to 20% AUC increase with quercetin co-administration [7].

Putting the Numbers Together

A 15% to 36% increase in AUC is pharmacologically meaningful for a drug like lemborexant, where the dose-response curve is steep and excess sedation carries real safety consequences (falls, impaired driving, next-day somnolence). The effect does not reach the 4-fold increase seen with strong CYP3A4 inhibitors, but it overlaps with the range the FDA considers clinically relevant for moderate inhibitors.

Pharmacodynamic Overlap: Sedation Stacking

Beyond enzyme inhibition, quercetin has mild central nervous system effects that could compound Dayvigo's sedation.

Quercetin's Antihistamine Properties

Quercetin stabilizes mast cells and reduces histamine release, which is why it appears in many allergy-support supplements [8]. Histamine is also a wake-promoting neurotransmitter. Reducing histamine signaling, even modestly, could add to the sleep-promoting action of an orexin antagonist. The magnitude of this effect at standard supplement doses is likely small, but it creates a pharmacodynamic layer on top of the pharmacokinetic interaction.

GABAergic Activity

Some preclinical data suggest quercetin has weak positive allosteric effects at GABA-A receptors [9]. A 2016 rodent study in Phytomedicine showed anxiolytic-like behavior at high oral doses [9]. Whether this translates to humans at 500 to 1,000 mg supplement doses is unproven, but the directional effect (more sedation) aligns with the pharmacokinetic risk.

What the Dayvigo Label Says About CYP3A4 Inhibitors

The FDA prescribing information for Dayvigo provides explicit guidance [3]:

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin): contraindicated. Do not co-administer.

Moderate CYP3A4 inhibitors (fluconazole, erythromycin, verapamil, diltiazem): reduce Dayvigo to a maximum of 5 mg per night.

Weak CYP3A4 inhibitors: no specific dose adjustment recommended, but the label advises monitoring.

Quercetin at typical supplement doses (500 to 1,000 mg/day) behaves as a weak-to-moderate CYP3A4 inhibitor based on available clinical pharmacokinetic data [6][7]. The practical implication: if you are taking quercetin and Dayvigo together, the 5 mg lemborexant dose is the safer choice.

Dose-Separation Strategy

Separating the timing of quercetin and Dayvigo doses can reduce peak enzyme inhibition at the moment lemborexant enters the bloodstream.

Why Timing Helps

Quercetin's plasma half-life is approximately 3 to 5 hours after a single oral dose, though some metabolites persist longer [4]. Taking quercetin in the morning and Dayvigo at bedtime (the labeled time of administration) creates a window of 10 to 14 hours, well beyond quercetin's peak plasma concentration. This does not eliminate the interaction entirely, because some residual CYP3A4 inhibition persists, but it meaningfully reduces the magnitude.

Practical Schedule

A reasonable approach for most patients:

• Morning (with breakfast): quercetin 500 mg
• Bedtime (within 5 minutes of going to bed): lemborexant 5 mg

If a second quercetin dose is needed (some regimens use 500 mg twice daily for allergy or antioxidant support), take it at midday rather than evening.

What Not to Do

Do not take quercetin and Dayvigo within 2 hours of each other. Do not exceed 1,000 mg of quercetin per day without discussing it with your provider, as higher doses increase CYP3A4 inhibition and unpredictable bioavailability spikes (especially with newer lipid-formulated or phytosome-bound quercetin products that boost absorption 10- to 20-fold) [10].

Monitoring If You Are Already Taking Both

Many patients are already combining quercetin and Dayvigo when they first learn about this interaction. That is not cause for alarm, but it does warrant a structured check.

Signs of Excess Sedation

Watch for these symptoms, particularly during the first two weeks after starting or increasing either agent:

• Difficulty waking up or feeling "drugged" in the morning
• Excessive daytime sleepiness beyond what you experienced on Dayvigo alone
• Slowed reaction time, especially while driving
• Memory lapses or confusion after waking
• Balance problems or near-falls during nighttime bathroom trips

When to Contact Your Prescriber

Contact your doctor if you experience any of the symptoms above, if you plan to increase your quercetin dose, or if you switch to a high-bioavailability quercetin formulation (such as quercetin phytosome or quercetin dihydrate). These newer formulations can deliver 5 to 20 times more quercetin to the systemic circulation than standard powder-in-capsule products [10], effectively shifting the interaction from weak to moderate territory.

Lab Monitoring

No specific lab test tracks this interaction. However, if you are also taking other CYP3A4 substrates (statins like atorvastatin, calcium channel blockers like amlodipine, immunosuppressants like tacrolimus), the cumulative enzyme inhibition from quercetin matters. A comprehensive medication-supplement review by a pharmacist can flag these overlapping risks.

Special Populations

Older Adults

The SUNRISE-2 trial included patients aged 65 and older and found higher rates of somnolence in this age group even at the 5 mg dose [2]. Adding quercetin-mediated CYP3A4 inhibition on top of age-related declines in hepatic clearance creates a compounding risk. Older adults should use the lowest effective quercetin dose or consider alternative flavonoids (like rutin) with less CYP3A4 inhibition.

Hepatic Impairment

Lemborexant AUC increases approximately 50% in moderate hepatic impairment (Child-Pugh B) per the FDA label, and the drug is not recommended in severe hepatic impairment [3]. Patients with liver disease who take quercetin face a double hit: reduced baseline clearance plus enzymatic inhibition. This combination should be avoided unless directly supervised by a hepatologist or sleep medicine specialist.

CYP3A4 Poor Metabolizers

Genetic variation in CYP3A4 expression (CYP3A4*22 and other reduced-function alleles) affects roughly 5% to 8% of people of European descent [11]. These individuals already clear lemborexant more slowly. For them, even the weak inhibition from standard-dose quercetin could produce a disproportionate rise in drug levels. Pharmacogenomic testing is not routinely ordered for Dayvigo, but if results are available, they should inform this decision.

Alternatives to Quercetin That Avoid This Interaction

If you take quercetin primarily for allergy support or antioxidant benefits, several alternatives have minimal CYP3A4 interaction potential.

For allergy/mast cell stabilization: Vitamin C (1,000 mg/day), stinging nettle extract (300 to 600 mg/day), and butterbur extract (standardized to petasins, 75 mg twice daily) support histamine management without meaningful CYP3A4 inhibition [12].

For antioxidant/anti-inflammatory support: N-acetylcysteine (600 to 1,200 mg/day) and curcumin (with piperine, though piperine itself inhibits CYP3A4, so use a phytosome formulation without piperine) offer overlapping benefits. Resveratrol at doses below 500 mg/day has limited CYP3A4 effects, though higher doses can become inhibitory [13].

Discuss any supplement switch with your provider, as the replacement may carry its own interaction profile.

The Bottom Line on Combining Quercetin and Dayvigo

This interaction is real but manageable. Quercetin at 500 to 1,000 mg/day behaves as a weak-to-moderate CYP3A4 inhibitor in vivo, and Dayvigo relies almost exclusively on CYP3A4 for clearance. The combination can raise lemborexant levels by an estimated 15% to 36%, enough to increase next-day drowsiness and impair driving in susceptible individuals.

Three concrete steps reduce the risk: use the 5 mg Dayvigo dose (not 10 mg), take quercetin in the morning and Dayvigo at bedtime, and avoid high-bioavailability quercetin formulations unless your prescriber has accounted for the stronger inhibition they produce. Patients over 65 or those with liver disease should consider dropping quercetin or switching to an alternative supplement with a cleaner CYP3A4 profile. Report any new morning grogginess, balance trouble, or driving difficulty to your prescriber within 48 hours of onset.